Uploaded June 2025 | Updated September 2026, 38 minutes ago
Why do some cancer patients respond well to immunotherapy while others suffer severe side effects? Traditional immune profiling methods often miss the key genetic drivers behind these variable outcomes, leaving critical questions unanswered.
In this webinar, Dr. Melissa Smith, CEO of ClareoBio and Associate Professor at the University of Louisville, explores how HiFi sequencing provides a comprehensive view of the adaptive immune system. Discover how resolving full-length B-cell and T-cell receptor transcripts, along with complex immune loci, uncovers a wealth of genetic variation that short-read methods cannot capture.
Learn how this detailed immunogenomic profiling can identify variants linked to therapeutic response and immune-related adverse events (IRAEs). These insights can advance biomarker discovery, inform drug development, and move us closer to more precise and effective cancer immunotherapies.
00:00 Introduction to the webinar
01:21 Multi-omic cancer research with HiFi sequencing
02:34 PacBio's end-to-end DNA workflow
03:02 Understanding Fiber-Seq for chromatin accessibility
04:41 HiFi sequencing for FFPE samples
05:38 RNA sequencing: capturing full-length isoforms
08:20 Dr. Melissa Smith: precision immunogenomic profiling
09:04 The challenge of immunotherapy side effects
10:33 Why immunogenomic loci are poorly studied
12:05 V(D)J recombination and locus complexity
14:11 Using long reads to resolve immune haplotypes
17:35 Variation extends to T-cell receptor loci
19:15 Linking TCR variation to immunotherapy response
22:19 How genetic variants affect gene expression (eQTLs)
28:34 Profiling immune repertoires at the RNA level
31:21 FLAIR-seq: full-length repertoire sequencing
38:03 A case study in Myasthenia Gravis (MG)
44:49 Introducing Clareo Biosciences
48:20 Final thoughts and key takeaways
50:28 Live Q&A session
Subscribe for more insights from PacBio: youtube.com/@PacificBiosciences?sub_confirmation=1
Learn more about PacBio at pacb.com
Legal & Trademarks: Visit pacb.com/legal-and-trademarks
Why do some cancer patients respond well to immunotherapy while others suffer severe side effects? Traditional immune profiling methods often miss the key genetic drivers behind these variable outcomes, leaving critical questions unanswered.
In this webinar, Dr. Melissa Smith, CEO of ClareoBio and Associate Professor at the University of Louisville, explores how HiFi sequencing provides a comprehensive view of the adaptive immune system. Discover how resolving full-length B-cell and T-cell receptor transcripts, along with complex immune loci, uncovers a wealth of genetic variation that short-read methods cannot capture.
Learn how this detailed immunogenomic profiling can identify variants linked to therapeutic response and immune-related adverse events (IRAEs). These insights can advance biomarker discovery, inform drug development, and move us closer to more precise and effective cancer immunotherapies.
00:00 Introduction to the webinar
01:21 Multi-omic cancer research with HiFi sequencing
02:34 PacBio's end-to-end DNA workflow
03:02 Understanding Fiber-Seq for chromatin accessibility
04:41 HiFi sequencing for FFPE samples
05:38 RNA sequencing: capturing full-length isoforms
08:20 Dr. Melissa Smith: precision immunogenomic profiling
09:04 The challenge of immunotherapy side effects
10:33 Why immunogenomic loci are poorly studied
12:05 V(D)J recombination and locus complexity
14:11 Using long reads to resolve immune haplotypes
17:35 Variation extends to T-cell receptor loci
19:15 Linking TCR variation to immunotherapy response
22:19 How genetic variants affect gene expression (eQTLs)
28:34 Profiling immune repertoires at the RNA level
31:21 FLAIR-seq: full-length repertoire sequencing
38:03 A case study in Myasthenia Gravis (MG)
44:49 Introducing Clareo Biosciences
48:20 Final thoughts and key takeaways
50:28 Live Q&A session
Subscribe for more insights from PacBio: youtube.com/@PacificBiosciences?sub_confirmation=1
Learn more about PacBio at pacb.com
Legal & Trademarks: Visit pacb.com/legal-and-trademarks
